Quebec, Canada

Marie-Helene Tremblay

This inventor holds 1 USPTO granted patent. Top assignee: Augusta Spinco Corporation. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marie-Helene Tremblay. Retrieved from https://idiyas.com/inventor/marie-helene-tremblay-7atbdtp8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marie-Helene Tremblay: Patent Work in Diagnostic Testing

Introduction

Marie-Helene Tremblay is an inventor associated with Quebec, Canada. Her patent work includes a buffer composition intended to support nucleic acid-based testing for vaginal disorders.

Latest Patents

Tremblay is associated with one patent, titled “Buffer Compositions for Reducing Aggregation.” The disclosed compositions, kits, and methods support nucleic acid-based detection and identification of conditions such as vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis. The technology is designed to help maintain robust diagnostic performance when samples contain interfering substances, including gels found in clinical vaginal-swab samples. The record lists 1 patent.

Career Highlights

The patent record connects Tremblay’s work with Augusta Spinco Corporation. The invention focuses on addressing sample-related interference in diagnostic testing.

Collaborations

The listed coworkers associated with Tremblay include Jean-Sebastien Cote and Marie-Christine Fortin.

Conclusion

Marie-Helene Tremblay’s documented patent contribution concerns buffer compositions designed to improve the reliability of nucleic acid-based testing for vaginal disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…